drugset / Trial / NCT00003408

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

NCT00003408

Phase 2 Completed 40 enrolled Cancer Treatment Centers of America
Treatment

Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy with sargramostim, interleukin-2, and interferon alfa following chemotherapy and peripheral stem cell transplantation in treating patients who have cancer.

Timeline

Start
1998-04
Primary completion
Completion
2000-03

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic Intravenous
Subject interferon alfa-2b Protein / enzyme biologic Subcutaneous
Background sargramostim Protein / enzyme biologic Subcutaneous